Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents

Abstract

The impact of a designated cardiology team involving telemedicine home monitoring on the care of children with single-ventricle physiology after norwood palliation.

Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study

“…The clinical phenotype in the only individual in our cohort with MIS-C after breakthrough infection was similar to the phenotype in unvaccinated individuals, but was remarkable due to presentation with severe chest pain, which is rarely seen in unvaccinated children with MIS-C, but reported as an rare adverse event to vaccination. 11 Since the patient had completed the Pfizer-BioNTech vaccine 4 months before the development of MIS-C, vaccine-induced MIS-C was less plausible, despite severe chest pain being reported as the presenting symptom in vaccine-induced MIS-C. 16 The other cases of MIS-C reported after breakthrough infection in vaccinated individuals had a similar phenotype as in non-vaccinated children, with hypotension and several organs involved, but not severe chest pain as the initial presentation. 6,21 The estimation of the incidence of MIS-C is dependent on a precise number of MIS-C cases.…”

“…As part of the paediatric nationwide COVID-19 research project, all 18 departments had a principal investigator responsible for prospective realtime data collection to REDCap, a secure web application, including details on clinical characteristics, treatment, and outcome of patients with COVID-19-associated disease, including MIS-C, since March 12, 2020. 3,10,11 To ensure completeness of MIS-C cases identified by the prospective data collection, patients hospitalised with ICD-10 diagnosis codes for MIS-C (DB972B and DB972B1) were obtained through the Danish National Patient Registry. 12 We matched cases from the prospective realtime data collection and those identified through ICD-10 diagnosis codes through the unique social security number for each person in Denmark.…”

“…8 Denmark has comprehensive population registries and a national COVID-19 surveillance system holding nationwide test results from both public and private providers, as well as details of vaccination status for each individual using the unique, personal civil registration number. 9 A nation wide paediatric COVID-19 research project was established early on in the pandemic, with prospective real-time data collection of detailed phenotypes of COVID-19-associated diseases, including a cohort of cases of MIS-C. 3,10,11 We aimed to estimate the incidence of MIS-C and describe the clinical phenotype, following infection with the delta variant of SARS-CoV-2 according to vaccination status. Moreover, we aimed to compare the incidence and clinical phenotype of MIS-C from our cohort during the pre-delta era.…”

Effectiveness and Safety of SARS-CoV-2 Vaccines among Children and Adolescents: A Systematic Review and Meta-Analysis

“…There were no reports of myocarditis and pericarditis in our study, but this did not mean that myocarditis or pericarditis was not worthy of attention. According to the survey, 350 cases of myocarditis occurred among 8.9 million adolescents who have been vaccinated with BNT162b2 vaccine in the United States [ 14 ]; there were 97 males and 16 females with pericarditis, and myocarditis occurred in every million 12–17 year-old adolescents vaccinated with BNT162b2 vaccine in Denmark [ 30 ]. It reminded us that it was still necessary to monitor and follow up serious adverse events in children and adolescents vaccinated with SARS-CoV-2 vaccines, especially adverse events, such as pericarditis, myocarditis, and allergic purpura.…”

Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data

“…The prevalence of myocarditis was five times higher in the 16–30-year-old group (1/20,000) compared to that in the general population (1/100,000) vaccinated with the same vaccine [ 33 , 34 ]. In Danish adolescents, the incidence of myopericarditis after BNT162b2 vaccination was revealed as 97 males and 16 females per million among individuals 12–17 years of age [ 35 ]. The present study similarly found that the risk of myocarditis following the BNT162b2 vaccination among adolescents (12–17 years old) was significantly higher in males than in females.…”